Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis

Authors: Ya-nan Ji, Qin Wang, Jun Xue

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Various studies examined the relationship between p53 expression with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results. Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 expression and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 24 studies that evaluated the correlation between p53 expression and survival in patients with HCC. Combined hazard ratios suggested that p53 expression had an unfavorable impact on overall survival (OS) (HR (hazard ratio) = 1.55, 95 % CI (confidence interval) 1.36–1.74) and disease-free survival (DFS) (HR = 1.54, 95 % CI 1.21–1.88) in patients with HCC. No significant heterogeneity was observed among 20 studies for OS (P = 0.786) and among 11 studies for DFS (P = 0.698). P53 expression indicates a poor prognosis for patients with hepatocellular carcinoma.
Literature
1.
2.
Lai PB, Chi TY, Chen GG. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis. 2007;12(2):387–93.PubMedCrossRef
3.
Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 1994;54(11):2914–8.PubMed
4.
Park NH, Chung YH, Youn KH, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol. 2001;33(5):397–401.PubMedCrossRef
5.
Terris B, Laurent-Puig P, Belghitti J, et al. Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H, and p53 expression in a large series of resected hepatocellular carcinoma in France. Int J Cancer. 1997;74(6):614–9.PubMedCrossRef
6.
Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumor progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006;209(4):549–58.PubMedCrossRef
7.
Atta MM, El-Masry SA, Abdel-Hameed M, Baiomy HA, Ram-adan NE. Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma. Clin Biochem. 2008;41(14–15):1131–9.PubMedCrossRef
8.
9.
10.
11.
12.
Zhan P, Wang Q, Qian Q, Yu LK. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials. Chin Clin Oncol. 2013. doi:10.​3978/​j.​issn.​2304-3865.​2013.​01.​02.
13.
14.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef
15.
Yusuf S, Peto R, Lewis J, et al. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–71.PubMedCrossRef
16.
17.
Egger M, Smith GD, Schneider M. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
18.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
19.
Soini Y, Virkajärvi N, Lehto VP, Pääkkö P. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer. 1996;73(9):1025–30.PubMedCentralPubMedCrossRef
20.
Mise K, Tashiro S, Yogita S, et al. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res. 1998;4(6):1475–82.PubMed
21.
Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res. 1998;18(1B):555–64.PubMed
22.
Wu PC, Lau VK, Fang JW, et al. Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver. 1999;19(5):444–51.PubMedCrossRef
23.
Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver. 2000;20(3):209–15.PubMedCrossRef
24.
Qin LX, Tang ZY, Ma ZC, et al. p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol. 2002;8(3):459–63.PubMed
25.
Kobayashi T, Sugawara Y, Shi YZ, Makuuchi M. Telomerase expression and p53 status in hepatocellular carcinoma. Am J Gastroenterol. 2002;97(12):3166–71.PubMedCrossRef
26.
Chiu CT, Yeh TS, Hsu JC, Chen MF. Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci. 2003;48(4):670–6.PubMedCrossRef
27.
Osada S, Saji S, Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol. 2004;85(1):48–54.PubMedCrossRef
28.
Anzola M, Saiz A, Cuevas N, et al. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma. J Viral Hepat. 2004;11(6):502–10.PubMedCrossRef
29.
Qin HX, Nan KJ, Yang G, et al. Expression and clinical significance of TAp73 a, p53, PCNA, and apoptosis in hepatocellular carcinoma. World J Gastroenterol. 2005;11(18):2709–13.PubMed
30.
Schöniger-Hekele M, Hänel S, Wrba F, Müller C. Hepatocellular carcinoma-survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int. 2005;25(1):62–9.PubMedCrossRef
31.
Guzman G, Alagiozian-Angelova V, Layden-Almer JE, et al. p53, Ki-67, and serum alpha fetoprotein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Modern Pathol. 2005;18(11):1498–503.CrossRef
32.
Sung CO, Yoo BC, Koh KC, Cho JW, Park CK. Prognostic significance of p53 overexpression after hepatic resection of hepatocellular carcinoma. Korean J Gastroenterol. 2005;45(6):425–30.PubMed
33.
Gianni S, Cecchetto A, Altavilla G, et al. Tumor staging, morphology, and p53 overexpression concur in predicting survival in hepatocellular carcinoma. J Intern Med. 2005;257(4):367–73.PubMedCrossRef
34.
Guo RP, Zhong C, Shi M, et al. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132(9):547–55.PubMedCrossRef
35.
Hu TH, Wang CC, Huang CC, et al. Downregulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep. 2007;18(6):1417–26.PubMed
36.
Stroescu C, Dragnea A, Ivanov B, et al. Expression of p53, Bcl-2, VEGF, Ki67, and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointest Liver Dis. 2008;17(4):411–7.
37.
Umemura A, Itoh Y, Itoh K, et al. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology. 2008;47(2):493–502.PubMedCrossRef
38.
Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med. 2009;7:110.PubMedCentralPubMedCrossRef
39.
Liu AW, Cai J, Zhao XL, et al. The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma. J Clin Pathol. 2009;62(11):1003–8.PubMedCrossRef
40.
Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012;7(9):e45119.PubMedCentralPubMedCrossRef
41.
Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, et al. A morpho-molecular prognostic model for hepatocellular carcinoma. Br J Cancer. 2012;107(2):334–9.PubMedCentralPubMedCrossRef
42.
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953–62.PubMedCrossRef
43.
Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130:187–96.PubMedCrossRef
44.
Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, et al. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48(15):2328–38.PubMedCentralPubMedCrossRef
45.
Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.CrossRef
Metadata
Title
TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis
Authors
Ya-nan Ji
Qin Wang
Jun Xue
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1228-7

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro

Review

The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis

Research Article

Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells

Research Article

Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis

Research Article

High expression of MACC1 predicts poor prognosis in patients with osteosarcoma

Research Article

Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits